Non-Small Cell Lung Cancer
Conditions
Brief summary
This is a randomized, Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab in combination with cisplatin or carboplatin + pemetrexed compared with treatment with cisplatin or carboplatin + pemetrexed in participants who are chemotherapy-naive and have Stage IV non-squamous NSCLC. Eligible participants will be randomized by a 1:1 ratio into 2 groups: Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) and Arm B (Carboplatin or Cisplatin + Pemetrexed). The study will be conducted in two phases: Induction Phase and Maintenance Phase.
Interventions
DRUGAtezolizumab
Participants received IV infusion of 1200 mg atezolizumab on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
DRUGCarboplatin
Participants received IV infusion of carboplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period with doses calculated using Calvart formula.
DRUGCisplatin
Participants received IV infusion of 75 mg/m\^2 cisplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period.
DRUGPemetrexed
Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Histologically or cytologically confirmed, Stage IV non-squamous NSCLC. Participants with tumors of mixed non-small cell histology (i.e., squamous and non-squamous) are eligible if the major histological component appears to be non-squamous * No prior treatment for Stage IV non-squamous NSCLC. Participants with a sensitizing mutation in the epidermal growth factor receptor (EGFR) gene or with an anaplastic lymphoma kinase (ALK) fusion oncogene are excluded. Participants with unknown EGFR and ALK status require test results at screening from a local or central laboratory * Participants who have received prior neo-adjuvant, radiotherapy, adjuvant chemotherapy, or chemoradiotherapy with curative intent for non-metastatic disease must have experienced a treatment-free interval of at least 6 months from randomization since the last dose of chemotherapy and/or radiotherapy * Participants should submit a pre-treatment tumor tissue sample if available before or within 4 weeks after enrollment. If tumor tissue is not available, participants are still eligible * For participants enrolled in the extended China enrollment phase: current resident of mainland China, Hong Kong, or Taiwan and of Chinese ancestry * Measurable disease, as defined by RECIST v1.1 * Adequate hematologic and end organ function * For women of childbearing potential: agreement to remain abstinent or use contraceptive methods that result in a failure rate of less than (\<) 1 percent (%) per year during the treatment period and for at least 5 months after the last dose of atezolizumab or 6 months after the last dose of cisplatin * For men: agreement to remain abstinent or use contraceptive measures and agreement to refrain from donating sperm
Exclusion criteria
Cancer-Specific Exclusions * Participants with a sensitizing mutation in the EGFR gene or an ALK fusion oncogene * Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments * Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for greater than or equal to (\>= 2) weeks prior to randomization * Leptomeningeal disease * Uncontrolled tumor-related pain * Uncontrolled or symptomatic hypercalcemia (greater than \[\>\] 1.5 millimole/Liter ionized calcium or calcium \>12 milligrams/deciliter or corrected serum calcium \>upper limit of normal) * Malignancies other than NSCLC within 5 years prior to randomization * Known tumor programmed death-ligand 1 (PD-L1) expression status from other clinical studies (e.g., participants whose PD-L1 expression status was determined during screening for entry into a study with anti-PD-1 or anti-PD L1 antibodies but were not eligible are excluded) General Medical Exclusions: * History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins * History of certain autoimmune disease * History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis * All participants will be tested for human immunodeficiency virus (HIV) prior to the inclusion into the study and HIV-positive participants will be excluded from the clinical study * Severe infections within 4 weeks prior to randomization * Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction or cerebrovascular accident within 3 months prior to randomization, unstable arrhythmias, or unstable angina * Illness or condition that may interfere with a participant's capacity to understand, follow, and/or comply with study procedures
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Randomization up to approximately 39 months | PFS is defined as the time from randomization to the first occurrence of disease progression as determined by the investigator using RECIST v1.1 or death from any cause, whichever occurred first. |
| Overall Survival (OS) | Randomization up to approximately 39 months | OS is defined as time from randomization to death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) Assessed by the Investigator Using RECIST V1.1 | Randomization up to approximately 25 months | An objective response is defined as either an unconfirmed CR or a PR, as determined by the investigator using RECIST v1.1. Objective Response Rate is defined as the proportion of patients who had an objective response. |
| Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 | Randomization up to approximately 25 months | DOR is defined as the time interval from the date of the first occurrence of a CR or PR (whichever status is recorded first) until the first date that progressive disease or death is documented, whichever occurs first. |
| Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Baseline up to 3 and 6 months after disease progression or loss of clinical benefit (up to approximately 25 months) | EORTC QLQ-C30 is a validated and reliable self-report measure that consists of 30 questions that assess five aspects of patient functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, pain), global health/quality of life, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). EORTC QLQ-C30 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life); however a high score for a symptom scale or item represents a high level of symptomatology or problems. A ≥10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al. 1998). |
| Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Baseline up to 3 and 6 months after disease progression or loss of clinical benefit (up to approximately 25 months) | The EORTC QLQ-LC13 module incorporates one multiple item scale to assess dyspnea and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. The EORTC QLQ-LC13 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life); however, a high score for a symptom scale or item represents a high level of symptomatology or problems. A≥10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al. 1998). |
| Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Baseline up to 3 and 6 months after disease progression or loss of clinical benefit (up to approximately 25 months) | Change from baseline per SILC scale will be analyzed for each lung cancer symptoms scores. SILC questionnaire comprises 3 individual symptoms & are scored at individual symptom level, thus have a dyspnea score, chest pain score, & cough score. There are a total of 9 questions in SILC questionnaire, each question has a minimum value of 0 & maximum value of 4. Each individual symptom score is calculated as average of responses for symptom items. 'Chest pain' score is mean of question 1 & 2, 'Cough' score is mean of question 3 & 4 and 'Dyspnea' score is mean of question 5 to 9 in SILC questionnaire. An increase in score is suggestive of a worsening in symptomology. A score change of ≥0.3 points for dyspnea & cough symptom scores is considered to be clinically significant; whereas a score change of≥0.5 points for chest pain score is considered to be clinically significant. |
| Overall Survival Rate at Year 1 | Year 1 | The Overall Survival Rate at the 1-year landmark time point is defined as the probabilities that participants are alive 1-year after randomization. |
| Maximum Observed Serum Atezolizumab Concentration (Cmax) | Day 1 of Cycle 1 (Cycle length=21 days) | Maximum observed serum atezolizumab concentration (Cmax) after infusion (Arm A) |
| Plasma Concentrations for Carboplatin in Arm A(Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) | Prd (0 h), 5-10 minutes (mins) before end of carboplatin infusion (infusion duration=1-2 h), 1 h post-infusion on D1 of Cy1,3 (Cy length=21 days) | — |
| Plasma Concentrations for Cisplatin in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) | Prd (0 h), 5-10 mins before end of cisplatin infusion (infusion duration=30-60 mins), 1 h post-infusion on D1 of Cy1,3 (Cy length=21 days) | — |
| Plasma Concentrations for Pemetrexed in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) | Prd (0 h), 5-10 mins before end of pemetrexed infusion (infusion duration=10 mins), 1 h post-infusion on D1 of Cy1,3 (Cy length=21 days) | — |
| Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) of Atezolizumab | Prd (0 h) on D1 of Cy1,2,3,4,8,16 (Cy length=21 days) and thereafter on D1 of every 8th cycle, at treatment discontinuation & then every 30 days (up to 120 days) after last dose of atezolizumab (up to app 25 months) | Baseline prevalence and post-baseline incidence of anti-drug antibodies (ADA) to Atezolizumab in the Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) |
| Minimum Observed Serum Atezolizumab Concentration (Cmin) | Predose (Prd; 0 hour [h]) on D1 of Cy 2,3,4,8,16 (Cy length=21 days) and thereafter on D1 of every 8th cycle (up to approximately 25 months) | Minimum observed serum atezolizumab concentration (Cmin) prior to infusion at selected cycles (Arm A) |
| Overall Survival Rate Year 2 | Year 2 | The Overall Survival Rate at the 2-year landmark time point is defined as the probabilities that participants are alive 2-years after randomization. |
Countries
Argentina, Australia, Austria, Belgium, Bulgaria, Chile, China, France, Hungary, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Netherlands, Peru, Portugal, Romania, Russia, South Korea, Spain, Taiwan, Ukraine, United Kingdom, United States
Participant flow
Pre-assignment details
The study is considered Completed because the planned study activities and analyses have been performed.
Participants by arm
| Arm | Count |
|---|---|
| Arm B (Carboplatin or Cisplatin + Pemetrexed) Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase will begin maintenance therapy. Participants will receive IV infusion of 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period. | 286 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period. | 292 |
| Total | 578 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Death | 189 | 190 |
| Overall Study | Lost to Follow-up | 2 | 2 |
| Overall Study | Physician Decision | 0 | 1 |
| Overall Study | Protocol Violation | 1 | 0 |
| Overall Study | Randomization by Error | 2 | 0 |
| Overall Study | Study Terminated By Sponsor | 64 | 82 |
| Overall Study | Withdrawal by Subject | 28 | 17 |
Baseline characteristics
| Characteristic | Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Total | Arm B (Carboplatin or Cisplatin + Pemetrexed) |
|---|---|---|---|
| Age, Continuous | 63.3 Years STANDARD_DEVIATION 9.4 | 62.6 Years STANDARD_DEVIATION 9.4 | 61.8 Years STANDARD_DEVIATION 9.4 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 17 Participants | 38 Participants | 21 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 243 Participants | 484 Participants | 241 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 32 Participants | 56 Participants | 24 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 71 Participants | 136 Participants | 65 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 6 Participants | 4 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 25 Participants | 38 Participants | 13 Participants |
| Race (NIH/OMB) White | 193 Participants | 396 Participants | 203 Participants |
| Sex: Female, Male Female | 100 Participants | 194 Participants | 94 Participants |
| Sex: Female, Male Male | 192 Participants | 384 Participants | 192 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 189 / 286 | 190 / 292 |
| other Total, other adverse events | 255 / 274 | 275 / 291 |
| serious Total, serious adverse events | 91 / 274 | 149 / 291 |
Outcome results
Primary
Overall Survival (OS)
OS is defined as time from randomization to death from any cause.
Time frame: Randomization up to approximately 39 months
Population: The ITT population was defined as all randomized patients, whether or not the patients received the assigned treatment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Overall Survival (OS) | 13.6 Months |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Overall Survival (OS) | 17.5 Months |
p-value: 0.155995% CI: [0.709, 1.056]Log Rank
p-value: 0.154695% CI: [0.707, 1.056]Log Rank
Primary
Progression Free Survival (PFS) as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
PFS is defined as the time from randomization to the first occurrence of disease progression as determined by the investigator using RECIST v1.1 or death from any cause, whichever occurred first.
Time frame: Randomization up to approximately 39 months
Population: The ITT population was defined as all randomized patients, whether or not the patients received the assigned treatment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Progression Free Survival (PFS) as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | 5.2 Months |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Progression Free Survival (PFS) as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | 7.7 Months |
p-value: <0.000195% CI: [0.471, 0.671]Log Rank
Secondary
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score
The EORTC QLQ-LC13 module incorporates one multiple item scale to assess dyspnea and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. The EORTC QLQ-LC13 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life); however, a high score for a symptom scale or item represents a high level of symptomatology or problems. A≥10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al. 1998).
Time frame: Baseline up to 3 and 6 months after disease progression or loss of clinical benefit (up to approximately 25 months)
Population: ITT population with a non-missing baseline and at least a post-baseline PRO assessment (i.e., PRO evaluable population).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 36 | -1.67 Units on a scale | Standard Deviation 30.33 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 75 | -6.67 Units on a scale | Standard Deviation 14.91 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 81 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 84 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 87 | 0.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 90 | 0.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Time of First Pd | 2.19 Units on a scale | Standard Deviation 28.46 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Time of Last Tx Dose | -0.50 Units on a scale | Standard Deviation 27.11 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder:Survival Follow-Up Week 12 | 13.10 Units on a scale | Standard Deviation 30.55 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 21 | -6.00 Units on a scale | Standard Deviation 21.91 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 63 | -5.13 Units on a scale | Standard Deviation 18.49 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 69 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 78 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder:Survival Follow-Up Week 24 | 1.75 Units on a scale | Standard Deviation 28.27 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 3 | -2.50 Units on a scale | Standard Deviation 25.37 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 6 | -3.57 Units on a scale | Standard Deviation 27.2 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 9 | -1.85 Units on a scale | Standard Deviation 24.43 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 12 | -3.91 Units on a scale | Standard Deviation 28.46 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 15 | -6.33 Units on a scale | Standard Deviation 30.39 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 18 | -4.00 Units on a scale | Standard Deviation 26.97 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 21 | -6.00 Units on a scale | Standard Deviation 27.78 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 24 | -4.81 Units on a scale | Standard Deviation 28.05 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 27 | -3.85 Units on a scale | Standard Deviation 26.85 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 30 | 0.42 Units on a scale | Standard Deviation 29.76 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 33 | -0.46 Units on a scale | Standard Deviation 26.53 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 36 | -6.11 Units on a scale | Standard Deviation 31.59 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 39 | -5.00 Units on a scale | Standard Deviation 30.58 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 42 | -8.97 Units on a scale | Standard Deviation 27.31 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 45 | -13.19 Units on a scale | Standard Deviation 28.13 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 48 | -7.69 Units on a scale | Standard Deviation 31.96 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 51 | -17.59 Units on a scale | Standard Deviation 25.8 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 54 | -17.20 Units on a scale | Standard Deviation 27.04 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 57 | -11.54 Units on a scale | Standard Deviation 22.98 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 60 | -14.04 Units on a scale | Standard Deviation 27.92 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 63 | -10.26 Units on a scale | Standard Deviation 21.01 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 66 | -9.52 Units on a scale | Standard Deviation 25.2 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 69 | -11.11 Units on a scale | Standard Deviation 27.22 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 72 | -8.33 Units on a scale | Standard Deviation 23.57 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 75 | -13.33 Units on a scale | Standard Deviation 18.26 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 78 | -16.67 Units on a scale | Standard Deviation 23.57 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 81 | -16.67 Units on a scale | Standard Deviation 23.57 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 84 | -33.33 Units on a scale | Standard Deviation 0 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 87 | 0.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 90 | -33.33 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Time of First Pd | -6.01 Units on a scale | Standard Deviation 30.13 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Time of Last Tx Dose | -5.19 Units on a scale | Standard Deviation 28.05 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Survival Follow-Up Week 12 | 3.57 Units on a scale | Standard Deviation 29.17 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Survival Follow-Up Week 24 | -8.77 Units on a scale | Standard Deviation 24.45 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 3 | 0.21 Units on a scale | Standard Deviation 18.69 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 6 | 0.12 Units on a scale | Standard Deviation 17.13 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 9 | 0.89 Units on a scale | Standard Deviation 20.68 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 12 | 1.15 Units on a scale | Standard Deviation 21.82 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 15 | 0.00 Units on a scale | Standard Deviation 21.3 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 18 | -1.07 Units on a scale | Standard Deviation 18.9 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 21 | -3.56 Units on a scale | Standard Deviation 22.77 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 24 | -2.29 Units on a scale | Standard Deviation 21.75 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 39 | -5.00 Units on a scale | Standard Deviation 30.58 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 42 | 0.00 Units on a scale | Standard Deviation 28.77 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 45 | -0.69 Units on a scale | Standard Deviation 27.06 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 48 | -1.71 Units on a scale | Standard Deviation 27.52 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 54 | -1.08 Units on a scale | Standard Deviation 21.92 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 57 | -1.28 Units on a scale | Standard Deviation 22.07 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 51 | -2.78 Units on a scale | Standard Deviation 25.67 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 60 | -5.26 Units on a scale | Standard Deviation 20.07 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 66 | 4.76 Units on a scale | Standard Deviation 12.6 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 27 | -0.71 Units on a scale | Standard Deviation 22.32 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 30 | 1.25 Units on a scale | Standard Deviation 22.57 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 33 | 0.77 Units on a scale | Standard Deviation 21.45 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 36 | -1.11 Units on a scale | Standard Deviation 20.93 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 39 | 1.30 Units on a scale | Standard Deviation 26.91 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 42 | -0.43 Units on a scale | Standard Deviation 22.65 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 45 | -2.08 Units on a scale | Standard Deviation 26.6 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 48 | -4.56 Units on a scale | Standard Deviation 24.94 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 51 | -9.88 Units on a scale | Standard Deviation 21.87 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 54 | -6.45 Units on a scale | Standard Deviation 24.47 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 57 | -2.99 Units on a scale | Standard Deviation 23.42 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 60 | -11.11 Units on a scale | Standard Deviation 23.42 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 63 | -6.84 Units on a scale | Standard Deviation 15.41 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 66 | -9.52 Units on a scale | Standard Deviation 16.27 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 69 | -16.67 Units on a scale | Standard Deviation 21.94 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 72 | -5.56 Units on a scale | Standard Deviation 19.7 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 75 | -6.67 Units on a scale | Standard Deviation 14.91 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 78 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 81 | 11.11 Units on a scale | Standard Deviation 15.71 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 84 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 87 | 0.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 90 | 0.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Time of First PD | 2.37 Units on a scale | Standard Deviation 22.05 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Time of Last Tx Dose | 3.96 Units on a scale | Standard Deviation 22.74 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Survival Follow-Up Week 12 | 9.92 Units on a scale | Standard Deviation 25.9 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Survival Follow-Up Week 24 | 4.68 Units on a scale | Standard Deviation 17.5 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 3 | -1.25 Units on a scale | Standard Deviation 21.19 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 6 | 0.71 Units on a scale | Standard Deviation 25.15 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 9 | 0.82 Units on a scale | Standard Deviation 24.63 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 12 | -2.07 Units on a scale | Standard Deviation 24.6 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 15 | -1.46 Units on a scale | Standard Deviation 24.88 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 18 | -3.47 Units on a scale | Standard Deviation 26.38 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 21 | -3.33 Units on a scale | Standard Deviation 26.17 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 24 | -2.41 Units on a scale | Standard Deviation 26.89 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 27 | -5.13 Units on a scale | Standard Deviation 29.95 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 30 | -4.17 Units on a scale | Standard Deviation 29.71 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 33 | -0.46 Units on a scale | Standard Deviation 29.86 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 36 | -1.67 Units on a scale | Standard Deviation 31.55 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 39 | -3.89 Units on a scale | Standard Deviation 30.12 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 42 | -7.69 Units on a scale | Standard Deviation 29.24 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 45 | -6.25 Units on a scale | Standard Deviation 29.7 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 48 | -7.69 Units on a scale | Standard Deviation 29.08 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 51 | -11.11 Units on a scale | Standard Deviation 28.73 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 54 | -7.53 Units on a scale | Standard Deviation 29.45 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 57 | -1.28 Units on a scale | Standard Deviation 31.95 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 60 | 0.00 Units on a scale | Standard Deviation 22.22 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 63 | -5.13 Units on a scale | Standard Deviation 18.49 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 66 | -4.76 Units on a scale | Standard Deviation 23 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 69 | -16.67 Units on a scale | Standard Deviation 18.26 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 72 | -8.33 Units on a scale | Standard Deviation 23.57 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 75 | -6.67 Units on a scale | Standard Deviation 14.91 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 78 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 81 | 0.00 Units on a scale | Standard Deviation 47.14 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 84 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 87 | -33.33 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 90 | -33.33 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Time of First Pd | 6.56 Units on a scale | Standard Deviation 22.62 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Time of Last Tx Dose | 1.34 Units on a scale | Standard Deviation 25.26 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Survival Follow-Up Week 12 | 5.95 Units on a scale | Standard Deviation 36.35 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Survival Follow-Up Week 24 | 1.75 Units on a scale | Standard Deviation 17.48 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 3 | -4.69 Units on a scale | Standard Deviation 25.26 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 6 | -4.46 Units on a scale | Standard Deviation 23.14 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 9 | -2.88 Units on a scale | Standard Deviation 25.85 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 12 | -6.90 Units on a scale | Standard Deviation 23.54 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 15 | -3.89 Units on a scale | Standard Deviation 23.24 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 18 | -5.07 Units on a scale | Standard Deviation 25.77 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 24 | -2.41 Units on a scale | Standard Deviation 28.16 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 27 | -5.56 Units on a scale | Standard Deviation 28.13 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 30 | 1.25 Units on a scale | Standard Deviation 27.27 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 33 | -5.56 Units on a scale | Standard Deviation 25.02 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 72 | -8.33 Units on a scale | Standard Deviation 15.43 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 87 | 8.33 Units on a scale | Standard Deviation 16.67 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 33 | -3.02 Units on a scale | Standard Deviation 22.82 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 36 | -2.91 Units on a scale | Standard Deviation 27.26 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 36 | -2.91 Units on a scale | Standard Deviation 23.7 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 24 | -5.26 Units on a scale | Standard Deviation 30.11 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 72 | -7.58 Units on a scale | Standard Deviation 27.08 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 39 | -4.95 Units on a scale | Standard Deviation 22.31 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 75 | -8.70 Units on a scale | Standard Deviation 25.06 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 78 | -2.38 Units on a scale | Standard Deviation 24.33 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 39 | -3.99 Units on a scale | Standard Deviation 27.44 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 81 | 3.70 Units on a scale | Standard Deviation 11.11 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 42 | -6.33 Units on a scale | Standard Deviation 18.64 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 84 | 4.17 Units on a scale | Standard Deviation 21.36 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 90 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 87 | -16.67 Units on a scale | Standard Deviation 33.33 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 45 | -3.61 Units on a scale | Standard Deviation 21.36 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 90 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 93 | 0.00 Units on a scale | — |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 42 | -7.17 Units on a scale | Standard Deviation 26.4 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Time of First Pd | 1.90 Units on a scale | Standard Deviation 25.94 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 48 | -5.34 Units on a scale | Standard Deviation 21.49 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Time of Last Tx Dose | 0.33 Units on a scale | Standard Deviation 30.55 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 93 | 0.00 Units on a scale | — |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 51 | -1.69 Units on a scale | Standard Deviation 18.41 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 60 | -4.17 Units on a scale | Standard Deviation 27.75 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 45 | -5.63 Units on a scale | Standard Deviation 25.02 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 66 | -1.80 Units on a scale | Standard Deviation 31.37 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 54 | -1.90 Units on a scale | Standard Deviation 19.1 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 69 | -7.14 Units on a scale | Standard Deviation 22.87 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 12 | -4.37 Units on a scale | Standard Deviation 27.19 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder:Survival Follow-Up Week 12 | 5.56 Units on a scale | Standard Deviation 40.13 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 57 | -4.99 Units on a scale | Standard Deviation 22.99 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder:Survival Follow-Up Week 24 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 51 | -3.38 Units on a scale | Standard Deviation 27.53 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 48 | -4.64 Units on a scale | Standard Deviation 24.88 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 3 | -3.41 Units on a scale | Standard Deviation 26.9 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 60 | -0.40 Units on a scale | Standard Deviation 22.32 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 6 | -9.82 Units on a scale | Standard Deviation 26.5 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Time of First Pd | -3.81 Units on a scale | Standard Deviation 29.24 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 9 | -8.29 Units on a scale | Standard Deviation 31.37 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 63 | -6.55 Units on a scale | Standard Deviation 23.04 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 12 | -10.71 Units on a scale | Standard Deviation 31.66 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 51 | -5.49 Units on a scale | Standard Deviation 24.13 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 15 | -11.53 Units on a scale | Standard Deviation 29.05 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 66 | -4.50 Units on a scale | Standard Deviation 21.98 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 18 | -11.63 Units on a scale | Standard Deviation 27.92 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 30 | -3.33 Units on a scale | Standard Deviation 29.12 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 21 | -10.50 Units on a scale | Standard Deviation 30.76 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 69 | -4.76 Units on a scale | Standard Deviation 23.12 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 24 | -10.03 Units on a scale | Standard Deviation 33.08 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 54 | -4.29 Units on a scale | Standard Deviation 25.33 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 27 | -11.65 Units on a scale | Standard Deviation 34.4 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 72 | -1.52 Units on a scale | Standard Deviation 24.56 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 30 | -11.39 Units on a scale | Standard Deviation 31.31 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Time of Last Tx Dose | -0.83 Units on a scale | Standard Deviation 26.96 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 33 | -11.97 Units on a scale | Standard Deviation 30.91 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 75 | -6.76 Units on a scale | Standard Deviation 17.64 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 36 | -12.94 Units on a scale | Standard Deviation 30.33 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 57 | -5.80 Units on a scale | Standard Deviation 26.17 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 39 | -13.41 Units on a scale | Standard Deviation 32.43 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 78 | -3.17 Units on a scale | Standard Deviation 21.09 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 42 | -14.70 Units on a scale | Standard Deviation 29.68 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 15 | -7.34 Units on a scale | Standard Deviation 30.15 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 45 | -14.72 Units on a scale | Standard Deviation 27.83 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 81 | -9.88 Units on a scale | Standard Deviation 22.53 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 48 | -13.92 Units on a scale | Standard Deviation 32.29 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 60 | -3.57 Units on a scale | Standard Deviation 27.47 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 51 | -10.97 Units on a scale | Standard Deviation 34.48 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 84 | -6.94 Units on a scale | Standard Deviation 22.17 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 54 | -13.81 Units on a scale | Standard Deviation 33.81 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Survival Follow-Up Week 12 | -2.78 Units on a scale | Standard Deviation 32.48 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 57 | -13.53 Units on a scale | Standard Deviation 29.33 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 87 | -2.78 Units on a scale | Standard Deviation 18.98 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 60 | -10.71 Units on a scale | Standard Deviation 31.21 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 63 | -6.84 Units on a scale | Standard Deviation 25.57 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 63 | -12.82 Units on a scale | Standard Deviation 27.16 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 90 | 5.56 Units on a scale | Standard Deviation 23.57 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 66 | -12.61 Units on a scale | Standard Deviation 28.71 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 93 | 22.22 Units on a scale | — |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 69 | -11.90 Units on a scale | Standard Deviation 30.38 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 27 | -3.79 Units on a scale | Standard Deviation 26.72 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 72 | -16.67 Units on a scale | Standard Deviation 30.43 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Time of First PD | -0.16 Units on a scale | Standard Deviation 24.48 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 75 | -18.84 Units on a scale | Standard Deviation 28.12 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 66 | -4.50 Units on a scale | Standard Deviation 27.4 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 78 | -23.81 Units on a scale | Standard Deviation 27.51 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Time of Last Tx Dose | 0.44 Units on a scale | Standard Deviation 21.83 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 81 | -18.52 Units on a scale | Standard Deviation 33.79 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Survival Follow-Up Week 24 | -4.76 Units on a scale | Standard Deviation 29.99 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 84 | -29.17 Units on a scale | Standard Deviation 27.82 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Survival Follow-Up Week 12 | 13.43 Units on a scale | Standard Deviation 33.73 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 87 | -25.00 Units on a scale | Standard Deviation 31.91 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 69 | -5.95 Units on a scale | Standard Deviation 31.5 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 90 | -16.67 Units on a scale | Standard Deviation 23.57 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Week 93 | 0.00 Units on a scale | — |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Survival Follow-Up Week 24 | 4.76 Units on a scale | Standard Deviation 23 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Time of First Pd | -10.48 Units on a scale | Standard Deviation 28.68 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 18 | -6.26 Units on a scale | Standard Deviation 29.09 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Time of Last Tx Dose | -8.13 Units on a scale | Standard Deviation 28.78 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 3 | 0.81 Units on a scale | Standard Deviation 23.67 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Survival Follow-Up Week 12 | -6.94 Units on a scale | Standard Deviation 34.02 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 72 | -4.55 Units on a scale | Standard Deviation 23.67 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Coughing: Survival Follow-Up Week 24 | -14.29 Units on a scale | Standard Deviation 32.53 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 6 | -6.32 Units on a scale | Standard Deviation 24.39 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 3 | -1.41 Units on a scale | Standard Deviation 17.68 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 3 | -2.60 Units on a scale | Standard Deviation 24.78 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 6 | -1.17 Units on a scale | Standard Deviation 18.85 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 9 | -4.24 Units on a scale | Standard Deviation 25.57 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 9 | -3.34 Units on a scale | Standard Deviation 18.65 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 75 | 0.00 Units on a scale | Standard Deviation 20.1 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 12 | -0.46 Units on a scale | Standard Deviation 21.76 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 12 | -0.60 Units on a scale | Standard Deviation 27.65 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 15 | -1.12 Units on a scale | Standard Deviation 20.78 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 21 | -1.83 Units on a scale | Standard Deviation 28.71 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 18 | -3.88 Units on a scale | Standard Deviation 21.92 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 15 | -3.56 Units on a scale | Standard Deviation 25.6 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 21 | -1.45 Units on a scale | Standard Deviation 21.85 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 78 | 0.00 Units on a scale | Standard Deviation 26.15 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 36 | -3.24 Units on a scale | Standard Deviation 31.49 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 18 | -3.36 Units on a scale | Standard Deviation 26.77 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 39 | -3.99 Units on a scale | Standard Deviation 30.8 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 6 | -5.44 Units on a scale | Standard Deviation 25.19 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 42 | -8.60 Units on a scale | Standard Deviation 25.49 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 21 | -2.74 Units on a scale | Standard Deviation 25.22 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 45 | -6.06 Units on a scale | Standard Deviation 28.47 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 81 | 7.41 Units on a scale | Standard Deviation 14.7 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 24 | -4.76 Units on a scale | Standard Deviation 29.05 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 54 | -6.19 Units on a scale | Standard Deviation 25.56 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 33 | -1.94 Units on a scale | Standard Deviation 27.54 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 48 | -4.22 Units on a scale | Standard Deviation 29.89 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 27 | -2.71 Units on a scale | Standard Deviation 22.82 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 57 | -2.90 Units on a scale | Standard Deviation 26.65 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 84 | 4.17 Units on a scale | Standard Deviation 21.36 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 63 | -3.42 Units on a scale | Standard Deviation 27.35 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 30 | -3.06 Units on a scale | Standard Deviation 27.33 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 24 | -0.42 Units on a scale | Standard Deviation 23.82 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Arm Or Shoulder: Week 9 | -8.09 Units on a scale | Standard Deviation 28.73 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 27 | -2.08 Units on a scale | Standard Deviation 19.83 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Pain In Chest: Week 33 | -3.88 Units on a scale | Standard Deviation 28.12 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score | Dyspnoea: Week 30 | -2.78 Units on a scale | Standard Deviation 20.33 |
Secondary
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score
EORTC QLQ-C30 is a validated and reliable self-report measure that consists of 30 questions that assess five aspects of patient functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, pain), global health/quality of life, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). EORTC QLQ-C30 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life); however a high score for a symptom scale or item represents a high level of symptomatology or problems. A ≥10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al. 1998).
Time frame: Baseline up to 3 and 6 months after disease progression or loss of clinical benefit (up to approximately 25 months)
Population: ITT population with a non-missing baseline and at least a post-baseline PRO assessment (i.e., PRO evaluable population).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 75 | -6.67 Units on a scale | Standard Deviation 14.91 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 6 | -1.23 Units on a scale | Standard Deviation 23.16 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 9 | 0.20 Units on a scale | Standard Deviation 26.34 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 12 | -0.91 Units on a scale | Standard Deviation 27.57 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 15 | -1.67 Units on a scale | Standard Deviation 28.92 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 18 | -2.12 Units on a scale | Standard Deviation 24.85 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 21 | -5.67 Units on a scale | Standard Deviation 29.61 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 24 | -2.75 Units on a scale | Standard Deviation 28.74 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 27 | -2.53 Units on a scale | Standard Deviation 31.47 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 30 | -1.25 Units on a scale | Standard Deviation 32.45 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 33 | -1.83 Units on a scale | Standard Deviation 27.15 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 36 | -3.83 Units on a scale | Standard Deviation 30.49 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 39 | -1.67 Units on a scale | Standard Deviation 31.55 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 42 | -3.27 Units on a scale | Standard Deviation 28.48 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 45 | -6.25 Units on a scale | Standard Deviation 32 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 48 | -5.13 Units on a scale | Standard Deviation 32.03 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 51 | -14.81 Units on a scale | Standard Deviation 30.28 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 54 | -9.68 Units on a scale | Standard Deviation 35.69 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 57 | -7.69 Units on a scale | Standard Deviation 28.76 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 60 | -11.11 Units on a scale | Standard Deviation 25.57 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 63 | -7.69 Units on a scale | Standard Deviation 14.62 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 66 | -9.52 Units on a scale | Standard Deviation 16.27 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 69 | -16.67 Units on a scale | Standard Deviation 18.26 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 72 | -4.17 Units on a scale | Standard Deviation 27.82 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 3 | -1.95 Units on a scale | Standard Deviation 23.97 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 78 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 81 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 84 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 87 | 0.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 90 | 0.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Survival Follow-Up Week 12 | 9.20 Units on a scale | Standard Deviation 35.52 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Survival Follow-Up Week 24 | 5.26 Units on a scale | Standard Deviation 25.49 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 75 | -5.80 Units on a scale | Standard Deviation 19.21 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 51 | -2.92 Units on a scale | Standard Deviation 26.09 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 3 | -1.39 Units on a scale | Standard Deviation 25.17 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Survival Follow-Up Week 12 | 8.00 Units on a scale | Standard Deviation 42.25 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 6 | -4.71 Units on a scale | Standard Deviation 26.66 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 54 | -2.78 Units on a scale | Standard Deviation 27.26 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 9 | -6.33 Units on a scale | Standard Deviation 26.62 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 78 | -4.76 Units on a scale | Standard Deviation 25.68 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 12 | -3.39 Units on a scale | Standard Deviation 29.1 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 57 | -5.63 Units on a scale | Standard Deviation 28.72 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 15 | -2.44 Units on a scale | Standard Deviation 28.73 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 90 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 18 | -3.44 Units on a scale | Standard Deviation 30.43 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 60 | 0.00 Units on a scale | Standard Deviation 25.43 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 21 | -2.89 Units on a scale | Standard Deviation 31.83 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 81 | -11.11 Units on a scale | Standard Deviation 23.57 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 24 | -2.45 Units on a scale | Standard Deviation 31.85 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 63 | -5.13 Units on a scale | Standard Deviation 23.62 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 27 | -1.32 Units on a scale | Standard Deviation 27.13 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 93 | 0.00 Units on a scale | — |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 30 | -2.71 Units on a scale | Standard Deviation 28.5 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 66 | -1.80 Units on a scale | Standard Deviation 24.78 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 33 | -3.74 Units on a scale | Standard Deviation 30.14 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 84 | -4.17 Units on a scale | Standard Deviation 21.36 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 36 | -6.67 Units on a scale | Standard Deviation 31.49 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 69 | -3.57 Units on a scale | Standard Deviation 24.58 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 39 | -8.42 Units on a scale | Standard Deviation 29.16 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Survival Follow-Up Week 24 | -14.29 Units on a scale | Standard Deviation 17.82 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 42 | -9.12 Units on a scale | Standard Deviation 28.12 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 72 | 0.00 Units on a scale | Standard Deviation 27.22 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 45 | -2.11 Units on a scale | Standard Deviation 30.82 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 87 | 8.33 Units on a scale | Standard Deviation 16.67 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score | Dyspnoea: Week 48 | -7.41 Units on a scale | Standard Deviation 26.87 |
Secondary
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score
Change from baseline per SILC scale will be analyzed for each lung cancer symptoms scores. SILC questionnaire comprises 3 individual symptoms & are scored at individual symptom level, thus have a dyspnea score, chest pain score, & cough score. There are a total of 9 questions in SILC questionnaire, each question has a minimum value of 0 & maximum value of 4. Each individual symptom score is calculated as average of responses for symptom items. 'Chest pain' score is mean of question 1 & 2, 'Cough' score is mean of question 3 & 4 and 'Dyspnea' score is mean of question 5 to 9 in SILC questionnaire. An increase in score is suggestive of a worsening in symptomology. A score change of ≥0.3 points for dyspnea & cough symptom scores is considered to be clinically significant; whereas a score change of≥0.5 points for chest pain score is considered to be clinically significant.
Time frame: Baseline up to 3 and 6 months after disease progression or loss of clinical benefit (up to approximately 25 months)
Population: ITT population with a non-missing baseline and at least a post-baseline PRO assessment (i.e., PRO evaluable population).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 38 | 0.02 Units on a scale | Standard Deviation 1.03 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 22 | 0.04 Units on a scale | Standard Deviation 1.21 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 39 | 0.02 Units on a scale | Standard Deviation 1.19 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 64 | 0.15 Units on a scale | Standard Deviation 0.78 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 40 | -0.10 Units on a scale | Standard Deviation 1.15 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 1 | -0.08 Units on a scale | Standard Deviation 0.74 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 41 | -0.27 Units on a scale | Standard Deviation 1.1 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 65 | 0.11 Units on a scale | Standard Deviation 0.82 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 42 | -0.31 Units on a scale | Standard Deviation 1.04 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 23 | -0.08 Units on a scale | Standard Deviation 1.14 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 43 | -0.20 Units on a scale | Standard Deviation 1.04 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 18 | 0.35 Units on a scale | Standard Deviation 0.99 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 44 | 0.00 Units on a scale | Standard Deviation 1.04 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 21 | 0.03 Units on a scale | Standard Deviation 1.28 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 45 | -0.18 Units on a scale | Standard Deviation 1.14 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 24 | -0.02 Units on a scale | Standard Deviation 1.16 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 46 | -0.25 Units on a scale | Standard Deviation 1.04 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 20 | 0.30 Units on a scale | Standard Deviation 1.09 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 47 | -0.43 Units on a scale | Standard Deviation 1.09 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 2 | -0.01 Units on a scale | Standard Deviation 0.88 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 48 | -0.26 Units on a scale | Standard Deviation 1.16 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 21 | 0.22 Units on a scale | Standard Deviation 1.03 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 49 | -0.50 Units on a scale | Standard Deviation 1.07 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 22 | 0.16 Units on a scale | Standard Deviation 1.1 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 58 | -0.17 Units on a scale | Standard Deviation 1.05 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 50 | -0.37 Units on a scale | Standard Deviation 0.84 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 25 | 0.05 Units on a scale | Standard Deviation 1.24 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 51 | -0.45 Units on a scale | Standard Deviation 1.16 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 23 | 0.24 Units on a scale | Standard Deviation 1.05 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 52 | -0.29 Units on a scale | Standard Deviation 1.07 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 27 | 0.04 Units on a scale | Standard Deviation 1.17 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 53 | -0.24 Units on a scale | Standard Deviation 1.21 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 24 | 0.30 Units on a scale | Standard Deviation 0.98 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 54 | -0.27 Units on a scale | Standard Deviation 1.1 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 22 | -0.29 Units on a scale | Standard Deviation 1.11 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 55 | -0.10 Units on a scale | Standard Deviation 1.15 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 26 | 0.30 Units on a scale | Standard Deviation 1.05 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 56 | -0.30 Units on a scale | Standard Deviation 1.14 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 26 | -0.05 Units on a scale | Standard Deviation 1.14 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 57 | -0.41 Units on a scale | Standard Deviation 0.92 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 66 | 0.42 Units on a scale | Standard Deviation 0.92 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 29 | 0.06 Units on a scale | Standard Deviation 1.29 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 59 | -0.31 Units on a scale | Standard Deviation 0.93 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 68 | 0.33 Units on a scale | Standard Deviation 0.88 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 60 | -0.55 Units on a scale | Standard Deviation 1.04 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 8 | 0.03 Units on a scale | Standard Deviation 0.94 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 61 | -0.23 Units on a scale | Standard Deviation 1.15 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 30 | 0.01 Units on a scale | Standard Deviation 1.37 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 62 | 0.04 Units on a scale | Standard Deviation 1.03 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 70 | 0.25 Units on a scale | Standard Deviation 0.88 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 63 | -0.29 Units on a scale | Standard Deviation 1.18 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 90 | 0.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 64 | -0.45 Units on a scale | Standard Deviation 1.04 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 71 | 0.30 Units on a scale | Standard Deviation 0.97 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 65 | -0.61 Units on a scale | Standard Deviation 0.96 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 31 | 0.02 Units on a scale | Standard Deviation 1.09 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 66 | -0.17 Units on a scale | Standard Deviation 0.82 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 73 | 0.13 Units on a scale | Standard Deviation 1.31 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 67 | -0.64 Units on a scale | Standard Deviation 1.07 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 28 | 0.24 Units on a scale | Standard Deviation 1.18 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 68 | -0.75 Units on a scale | Standard Deviation 0.88 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 74 | 0.38 Units on a scale | Standard Deviation 1.11 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 69 | -0.57 Units on a scale | Standard Deviation 1.1 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 4 | 0.03 Units on a scale | Standard Deviation 0.91 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 70 | -0.83 Units on a scale | Standard Deviation 0.93 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 75 | 0.38 Units on a scale | Standard Deviation 1.11 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 71 | -0.90 Units on a scale | Standard Deviation 0.89 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 32 | 0.21 Units on a scale | Standard Deviation 1.21 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 72 | -1.25 Units on a scale | Standard Deviation 0.5 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 76 | 0.00 Units on a scale | Standard Deviation 0.5 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 73 | -0.63 Units on a scale | Standard Deviation 1.11 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 34 | 0.21 Units on a scale | Standard Deviation 1.27 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 74 | -0.63 Units on a scale | Standard Deviation 1.11 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 77 | -0.25 Units on a scale | Standard Deviation 0.35 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 75 | -0.63 Units on a scale | Standard Deviation 1.11 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 33 | 0.04 Units on a scale | Standard Deviation 1.17 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 76 | -1.00 Units on a scale | Standard Deviation 1 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 78 | -0.75 Units on a scale | Standard Deviation 0.35 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 77 | -0.50 Units on a scale | Standard Deviation 0.71 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 25 | 0.50 Units on a scale | Standard Deviation 1.05 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 78 | -1.00 Units on a scale | Standard Deviation 0 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 79 | 0.00 Units on a scale | Standard Deviation 0.71 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 79 | -0.25 Units on a scale | Standard Deviation 0.35 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 35 | 0.33 Units on a scale | Standard Deviation 1.3 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 80 | -0.50 Units on a scale | Standard Deviation 0.71 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 80 | -0.25 Units on a scale | Standard Deviation 0.35 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 81 | -0.50 Units on a scale | Standard Deviation 0.71 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 9 | 0.06 Units on a scale | Standard Deviation 1 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 82 | -0.50 Units on a scale | Standard Deviation 0.71 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 81 | -0.25 Units on a scale | Standard Deviation 0.35 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 83 | -1.00 Units on a scale | Standard Deviation 0 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 82 | -0.75 Units on a scale | Standard Deviation 0.35 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 84 | -0.50 Units on a scale | Standard Deviation 0.71 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 36 | 0.15 Units on a scale | Standard Deviation 1.07 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 85 | 0.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 83 | -0.25 Units on a scale | Standard Deviation 0.35 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 86 | 0.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 48 | 0.02 Units on a scale | Standard Deviation 1.27 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 87 | 0.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 84 | 0.00 Units on a scale | Standard Deviation 0.71 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 88 | 0.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 37 | 0.15 Units on a scale | Standard Deviation 1.21 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 89 | 0.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 85 | -1.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 1 | 0.20 Units on a scale | Standard Deviation 0.83 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 91 | 0.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 86 | 0.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 38 | 0.12 Units on a scale | Standard Deviation 1.16 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 87 | -1.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 36 | 0.59 Units on a scale | Standard Deviation 1.06 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 88 | -1.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Time of First Pd | -0.08 Units on a scale | Standard Deviation 1.12 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 39 | 0.20 Units on a scale | Standard Deviation 1.23 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Time of Last Tx Dose | -0.15 Units on a scale | Standard Deviation 0.95 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 89 | -1.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 1 | 0.20 Units on a scale | Standard Deviation 0.82 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 55 | 0.12 Units on a scale | Standard Deviation 1.38 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 2 | 0.11 Units on a scale | Standard Deviation 0.76 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 90 | 0.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 3 | 0.10 Units on a scale | Standard Deviation 0.71 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 40 | 0.15 Units on a scale | Standard Deviation 1.31 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 4 | 0.21 Units on a scale | Standard Deviation 0.84 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 91 | 0.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 5 | 0.22 Units on a scale | Standard Deviation 0.82 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 6 | 0.23 Units on a scale | Standard Deviation 0.82 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 56 | 0.84 Units on a scale | Standard Deviation 1.15 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 7 | 0.30 Units on a scale | Standard Deviation 0.93 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 41 | -0.05 Units on a scale | Standard Deviation 1.06 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 8 | 0.35 Units on a scale | Standard Deviation 0.87 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 42 | -0.06 Units on a scale | Standard Deviation 1.07 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 9 | 0.34 Units on a scale | Standard Deviation 0.89 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 10 | 0.46 Units on a scale | Standard Deviation 0.93 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 10 | 0.03 Units on a scale | Standard Deviation 1.02 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 11 | 0.39 Units on a scale | Standard Deviation 1.01 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 43 | -0.22 Units on a scale | Standard Deviation 0.82 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 12 | 0.38 Units on a scale | Standard Deviation 0.96 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Time of First Pd | 0.28 Units on a scale | Standard Deviation 1.06 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 13 | 0.34 Units on a scale | Standard Deviation 0.96 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 6 | -0.05 Units on a scale | Standard Deviation 0.88 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 14 | 0.44 Units on a scale | Standard Deviation 0.95 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Time of Last Tx Dose | 0.17 Units on a scale | Standard Deviation 1.17 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 15 | 0.45 Units on a scale | Standard Deviation 0.94 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 2 | -0.13 Units on a scale | Standard Deviation 0.73 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 27 | 0.43 Units on a scale | Standard Deviation 1.17 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 16 | 0.37 Units on a scale | Standard Deviation 1.06 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 44 | -0.10 Units on a scale | Standard Deviation 1.29 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 17 | 0.35 Units on a scale | Standard Deviation 1.04 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 3 | -0.05 Units on a scale | Standard Deviation 0.77 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 28 | 0.46 Units on a scale | Standard Deviation 1.02 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 11 | 0.02 Units on a scale | Standard Deviation 0.96 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 29 | 0.43 Units on a scale | Standard Deviation 1.06 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 4 | -0.11 Units on a scale | Standard Deviation 0.89 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 30 | 0.45 Units on a scale | Standard Deviation 1.08 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 45 | -0.20 Units on a scale | Standard Deviation 1.24 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 31 | 0.35 Units on a scale | Standard Deviation 1.03 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 32 | 0.48 Units on a scale | Standard Deviation 1.03 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 33 | 0.36 Units on a scale | Standard Deviation 0.96 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 5 | -0.14 Units on a scale | Standard Deviation 0.83 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 34 | 0.47 Units on a scale | Standard Deviation 1.15 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 61 | 0.23 Units on a scale | Standard Deviation 0.83 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 35 | 0.42 Units on a scale | Standard Deviation 1 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 6 | -0.16 Units on a scale | Standard Deviation 0.85 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 46 | -0.06 Units on a scale | Standard Deviation 1.18 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 37 | 0.53 Units on a scale | Standard Deviation 1.17 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 7 | -0.22 Units on a scale | Standard Deviation 0.89 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 38 | 0.59 Units on a scale | Standard Deviation 1.06 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 39 | 0.65 Units on a scale | Standard Deviation 1.04 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 12 | -0.02 Units on a scale | Standard Deviation 0.96 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 40 | 0.62 Units on a scale | Standard Deviation 1.02 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 8 | -0.20 Units on a scale | Standard Deviation 0.89 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 41 | 0.63 Units on a scale | Standard Deviation 1.01 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 9 | -0.17 Units on a scale | Standard Deviation 0.91 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 42 | 0.50 Units on a scale | Standard Deviation 1.01 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 47 | 0.02 Units on a scale | Standard Deviation 1.09 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 43 | 0.32 Units on a scale | Standard Deviation 0.89 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 10 | -0.22 Units on a scale | Standard Deviation 0.95 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 44 | 0.58 Units on a scale | Standard Deviation 0.83 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 67 | 0.36 Units on a scale | Standard Deviation 0.85 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 45 | 0.49 Units on a scale | Standard Deviation 0.96 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 49 | -0.09 Units on a scale | Standard Deviation 1.07 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 46 | 0.55 Units on a scale | Standard Deviation 1.02 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 11 | -0.21 Units on a scale | Standard Deviation 0.99 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 47 | 0.53 Units on a scale | Standard Deviation 1.09 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 13 | -0.05 Units on a scale | Standard Deviation 1.02 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 48 | 0.55 Units on a scale | Standard Deviation 0.96 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 12 | -0.13 Units on a scale | Standard Deviation 1.05 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 49 | 0.63 Units on a scale | Standard Deviation 1.04 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 50 | -0.13 Units on a scale | Standard Deviation 0.99 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 50 | 0.52 Units on a scale | Standard Deviation 0.98 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 13 | -0.24 Units on a scale | Standard Deviation 1.05 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 51 | 0.67 Units on a scale | Standard Deviation 1.04 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 51 | -0.02 Units on a scale | Standard Deviation 0.77 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 52 | 0.72 Units on a scale | Standard Deviation 1.02 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 14 | -0.23 Units on a scale | Standard Deviation 0.98 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 53 | 0.81 Units on a scale | Standard Deviation 1.06 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 15 | 0.13 Units on a scale | Standard Deviation 1.16 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 54 | 0.82 Units on a scale | Standard Deviation 1.06 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 15 | -0.11 Units on a scale | Standard Deviation 1.03 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 55 | 0.77 Units on a scale | Standard Deviation 1.17 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 52 | 0.14 Units on a scale | Standard Deviation 1.06 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 16 | -0.20 Units on a scale | Standard Deviation 1.05 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 57 | 0.68 Units on a scale | Standard Deviation 1.16 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 14 | -0.07 Units on a scale | Standard Deviation 1.12 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 58 | 0.77 Units on a scale | Standard Deviation 1.06 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 17 | -0.20 Units on a scale | Standard Deviation 1.11 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 59 | 0.66 Units on a scale | Standard Deviation 0.9 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 53 | 0.13 Units on a scale | Standard Deviation 1.35 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 60 | 0.73 Units on a scale | Standard Deviation 0.96 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 18 | -0.19 Units on a scale | Standard Deviation 1.12 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 61 | 0.85 Units on a scale | Standard Deviation 1.04 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 16 | 0.02 Units on a scale | Standard Deviation 1.08 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 62 | 0.95 Units on a scale | Standard Deviation 1.05 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 19 | -0.25 Units on a scale | Standard Deviation 1.07 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 63 | 0.67 Units on a scale | Standard Deviation 1.01 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 54 | 0.11 Units on a scale | Standard Deviation 1.16 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 64 | 0.46 Units on a scale | Standard Deviation 0.78 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 20 | -0.25 Units on a scale | Standard Deviation 1.16 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 65 | 0.40 Units on a scale | Standard Deviation 0.66 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 69 | 0.07 Units on a scale | Standard Deviation 0.93 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 66 | 0.67 Units on a scale | Standard Deviation 0.74 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 21 | -0.19 Units on a scale | Standard Deviation 1.09 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 67 | 0.37 Units on a scale | Standard Deviation 0.76 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 18 | -0.06 Units on a scale | Standard Deviation 1.11 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 68 | 0.47 Units on a scale | Standard Deviation 0.8 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 56 | 0.13 Units on a scale | Standard Deviation 1.46 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 69 | 0.43 Units on a scale | Standard Deviation 0.8 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 23 | -0.34 Units on a scale | Standard Deviation 1.07 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 70 | 0.33 Units on a scale | Standard Deviation 0.83 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 72 | -0.13 Units on a scale | Standard Deviation 0.25 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 71 | 0.40 Units on a scale | Standard Deviation 0.91 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 24 | -0.27 Units on a scale | Standard Deviation 0.96 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 72 | -0.05 Units on a scale | Standard Deviation 0.25 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 25 | -0.24 Units on a scale | Standard Deviation 1.11 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 73 | 0.45 Units on a scale | Standard Deviation 1.04 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 26 | -0.25 Units on a scale | Standard Deviation 1.16 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 74 | 0.50 Units on a scale | Standard Deviation 1.01 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 57 | 0.12 Units on a scale | Standard Deviation 1.21 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 75 | 0.55 Units on a scale | Standard Deviation 0.97 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 27 | -0.19 Units on a scale | Standard Deviation 0.99 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 76 | -0.07 Units on a scale | Standard Deviation 0.12 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 19 | -0.15 Units on a scale | Standard Deviation 1.12 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 77 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 28 | -0.19 Units on a scale | Standard Deviation 1.04 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 78 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 58 | 0.27 Units on a scale | Standard Deviation 0.98 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 79 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 29 | -0.25 Units on a scale | Standard Deviation 1.13 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 80 | 0.10 Units on a scale | Standard Deviation 0.14 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 3 | -0.05 Units on a scale | Standard Deviation 0.92 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 81 | 0.10 Units on a scale | Standard Deviation 0.14 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 30 | -0.08 Units on a scale | Standard Deviation 1.12 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 82 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 59 | 0.23 Units on a scale | Standard Deviation 0.73 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 83 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 31 | -0.13 Units on a scale | Standard Deviation 1.13 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 84 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 19 | 0.30 Units on a scale | Standard Deviation 1.02 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 85 | 0.20 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 32 | 0.01 Units on a scale | Standard Deviation 1.09 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 86 | 0.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 20 | -0.02 Units on a scale | Standard Deviation 1.22 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 87 | 0.20 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 33 | 0.05 Units on a scale | Standard Deviation 1.17 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 88 | 0.20 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 60 | 0.14 Units on a scale | Standard Deviation 0.67 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 89 | 0.20 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 34 | -0.10 Units on a scale | Standard Deviation 1.09 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 90 | 0.20 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 17 | 0.02 Units on a scale | Standard Deviation 1.08 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 91 | 0.00 Units on a scale | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 35 | -0.27 Units on a scale | Standard Deviation 1.05 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 62 | 0.46 Units on a scale | Standard Deviation 0.72 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 36 | 0.01 Units on a scale | Standard Deviation 1.1 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 7 | 0.07 Units on a scale | Standard Deviation 1 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 37 | -0.11 Units on a scale | Standard Deviation 1.16 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Time of First Pd | 0.58 Units on a scale | Standard Deviation 0.99 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 63 | 0.25 Units on a scale | Standard Deviation 0.75 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Time of Last Tx Dose | 0.47 Units on a scale | Standard Deviation 0.95 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 5 | -0.02 Units on a scale | Standard Deviation 0.93 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 85 | 0.32 Units on a scale | Standard Deviation 1.53 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 86 | -0.15 Units on a scale | Standard Deviation 0.34 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 87 | -0.47 Units on a scale | Standard Deviation 0.23 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 88 | -0.70 Units on a scale | Standard Deviation 0.2 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 89 | -0.20 Units on a scale | Standard Deviation 0.57 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 90 | -0.50 Units on a scale | Standard Deviation 0.14 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 91 | -0.50 Units on a scale | Standard Deviation 0.14 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 92 | -0.70 Units on a scale | Standard Deviation 0.14 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 93 | -0.40 Units on a scale | Standard Deviation 0.28 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 94 | -0.80 Units on a scale | — |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 95 | -1.00 Units on a scale | — |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Time of First Pd | 0.40 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Time of Last Tx Dose | 0.18 Units on a scale | Standard Deviation 0.94 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 5 | -0.01 Units on a scale | Standard Deviation 0.88 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 1 | 0.30 Units on a scale | Standard Deviation 0.88 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 2 | 0.21 Units on a scale | Standard Deviation 0.85 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 3 | 0.06 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 4 | 0.03 Units on a scale | Standard Deviation 0.93 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 6 | -0.02 Units on a scale | Standard Deviation 0.92 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 7 | -0.04 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 8 | -0.07 Units on a scale | Standard Deviation 1.02 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 9 | -0.03 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 14 | 0.06 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 15 | 0.08 Units on a scale | Standard Deviation 0.94 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 17 | 0.00 Units on a scale | Standard Deviation 1.08 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 25 | 0.14 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 26 | 0.09 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 33 | 0.03 Units on a scale | Standard Deviation 0.92 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 47 | 0.09 Units on a scale | Standard Deviation 0.91 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 50 | 0.00 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 60 | -0.15 Units on a scale | Standard Deviation 1.17 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 67 | 0.02 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 72 | -0.22 Units on a scale | Standard Deviation 0.94 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 81 | -0.25 Units on a scale | Standard Deviation 0.89 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Time of Last Tx Dose | 0.13 Units on a scale | Standard Deviation 0.98 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 1 | -0.06 Units on a scale | Standard Deviation 0.89 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 8 | -0.28 Units on a scale | Standard Deviation 0.98 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 25 | -0.27 Units on a scale | Standard Deviation 1.1 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 24 | -0.29 Units on a scale | Standard Deviation 1.13 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 5 | 0.17 Units on a scale | Standard Deviation 0.91 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 9 | 0.17 Units on a scale | Standard Deviation 0.91 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 21 | 0.22 Units on a scale | Standard Deviation 1.05 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 25 | 0.28 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 31 | 0.15 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 32 | 0.16 Units on a scale | Standard Deviation 1.01 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 38 | 0.22 Units on a scale | Standard Deviation 1.07 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 10 | 0.02 Units on a scale | Standard Deviation 1.05 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 11 | 0.04 Units on a scale | Standard Deviation 1.09 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 12 | -0.01 Units on a scale | Standard Deviation 1.02 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 13 | 0.05 Units on a scale | Standard Deviation 0.97 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 16 | 0.08 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 18 | 0.12 Units on a scale | Standard Deviation 1.07 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 19 | 0.02 Units on a scale | Standard Deviation 1.01 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 20 | -0.01 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 21 | 0.01 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 22 | 0.02 Units on a scale | Standard Deviation 1.02 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 23 | 0.04 Units on a scale | Standard Deviation 0.96 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 24 | 0.09 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 27 | 0.04 Units on a scale | Standard Deviation 1.01 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 28 | 0.03 Units on a scale | Standard Deviation 0.93 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 29 | 0.04 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 30 | 0.04 Units on a scale | Standard Deviation 0.97 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 41 | 0.09 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 31 | 0.05 Units on a scale | Standard Deviation 0.88 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 32 | -0.01 Units on a scale | Standard Deviation 0.98 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 34 | 0.11 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 35 | 0.11 Units on a scale | Standard Deviation 0.98 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 36 | 0.17 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 37 | 0.06 Units on a scale | Standard Deviation 0.94 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 38 | 0.04 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 39 | 0.13 Units on a scale | Standard Deviation 1.01 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 40 | 0.04 Units on a scale | Standard Deviation 0.96 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 42 | 0.03 Units on a scale | Standard Deviation 1.02 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 43 | 0.13 Units on a scale | Standard Deviation 1.02 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 44 | 0.10 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 45 | 0.03 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 46 | 0.08 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 48 | 0.05 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 49 | 0.03 Units on a scale | Standard Deviation 0.9 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 51 | 0.12 Units on a scale | Standard Deviation 0.94 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 52 | 0.00 Units on a scale | Standard Deviation 1.11 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 53 | -0.01 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 54 | -0.08 Units on a scale | Standard Deviation 1.1 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 55 | 0.03 Units on a scale | Standard Deviation 1.14 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 56 | 0.04 Units on a scale | Standard Deviation 1.18 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 57 | -0.01 Units on a scale | Standard Deviation 1.15 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 58 | -0.12 Units on a scale | Standard Deviation 1.1 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 59 | -0.23 Units on a scale | Standard Deviation 1.01 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 61 | 0.00 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 62 | -0.04 Units on a scale | Standard Deviation 1.08 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 63 | -0.06 Units on a scale | Standard Deviation 1.09 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 64 | 0.09 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 17 | 0.15 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 18 | 0.22 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 19 | 0.22 Units on a scale | Standard Deviation 0.97 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 20 | 0.27 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 22 | 0.28 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 23 | 0.22 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 24 | 0.24 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 65 | -0.03 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 66 | 0.13 Units on a scale | Standard Deviation 1.05 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 68 | 0.12 Units on a scale | Standard Deviation 1.18 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 69 | -0.05 Units on a scale | Standard Deviation 1.1 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 70 | 0.03 Units on a scale | Standard Deviation 1.11 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 71 | 0.04 Units on a scale | Standard Deviation 1.09 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 73 | -0.10 Units on a scale | Standard Deviation 1.01 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 74 | -0.02 Units on a scale | Standard Deviation 1.14 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 75 | -0.07 Units on a scale | Standard Deviation 1.14 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 76 | -0.06 Units on a scale | Standard Deviation 1.2 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 77 | -0.21 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 78 | -0.25 Units on a scale | Standard Deviation 1.14 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 79 | -0.18 Units on a scale | Standard Deviation 1.2 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 80 | -0.12 Units on a scale | Standard Deviation 0.96 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 82 | 0.00 Units on a scale | Standard Deviation 1.25 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 83 | -0.50 Units on a scale | Standard Deviation 1.73 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 84 | -0.30 Units on a scale | Standard Deviation 1.57 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 85 | -0.20 Units on a scale | Standard Deviation 1.68 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 86 | -0.50 Units on a scale | Standard Deviation 1.73 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 87 | 0.50 Units on a scale | Standard Deviation 0.87 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 88 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 89 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 90 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 91 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 92 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 93 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 94 | 1.00 Units on a scale | — |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Week 95 | 0.50 Units on a scale | — |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Chest Pain: Time of First Pd | 0.20 Units on a scale | Standard Deviation 0.91 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 2 | -0.08 Units on a scale | Standard Deviation 0.9 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 3 | -0.07 Units on a scale | Standard Deviation 0.81 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 4 | -0.22 Units on a scale | Standard Deviation 0.85 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 5 | -0.33 Units on a scale | Standard Deviation 0.89 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 6 | -0.33 Units on a scale | Standard Deviation 0.91 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 7 | -0.22 Units on a scale | Standard Deviation 0.97 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 9 | -0.29 Units on a scale | Standard Deviation 0.97 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 26 | 0.24 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 10 | -0.35 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 11 | -0.33 Units on a scale | Standard Deviation 1.02 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 12 | -0.40 Units on a scale | Standard Deviation 0.96 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 13 | -0.37 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 14 | -0.34 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 15 | -0.33 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 16 | -0.33 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 17 | -0.31 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 18 | -0.31 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 19 | -0.36 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 20 | -0.39 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 21 | -0.36 Units on a scale | Standard Deviation 1.07 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 22 | -0.41 Units on a scale | Standard Deviation 1.08 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 23 | -0.44 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 26 | -0.22 Units on a scale | Standard Deviation 1.22 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 27 | -0.32 Units on a scale | Standard Deviation 1.11 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 28 | -0.32 Units on a scale | Standard Deviation 1.12 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 29 | -0.34 Units on a scale | Standard Deviation 1.11 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 30 | -0.34 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 31 | -0.37 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 32 | -0.45 Units on a scale | Standard Deviation 0.94 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 33 | -0.44 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 34 | -0.29 Units on a scale | Standard Deviation 1.02 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 35 | -0.32 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 36 | -0.31 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 37 | -0.37 Units on a scale | Standard Deviation 1.01 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 38 | -0.31 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 39 | -0.33 Units on a scale | Standard Deviation 0.98 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 40 | -0.35 Units on a scale | Standard Deviation 1.07 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 41 | -0.30 Units on a scale | Standard Deviation 1.09 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 42 | -0.31 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 43 | -0.37 Units on a scale | Standard Deviation 0.98 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 44 | -0.36 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 45 | -0.41 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 46 | -0.34 Units on a scale | Standard Deviation 1.17 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 47 | -0.29 Units on a scale | Standard Deviation 1.17 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 48 | -0.38 Units on a scale | Standard Deviation 1.08 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 49 | -0.40 Units on a scale | Standard Deviation 1.1 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 50 | -0.40 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 51 | -0.15 Units on a scale | Standard Deviation 1.1 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 52 | -0.10 Units on a scale | Standard Deviation 1.17 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 53 | -0.13 Units on a scale | Standard Deviation 1.17 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 54 | -0.16 Units on a scale | Standard Deviation 1.15 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 55 | -0.35 Units on a scale | Standard Deviation 1.13 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 56 | -0.26 Units on a scale | Standard Deviation 1.17 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 57 | -0.25 Units on a scale | Standard Deviation 1.1 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 58 | -0.45 Units on a scale | Standard Deviation 0.96 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 59 | -0.50 Units on a scale | Standard Deviation 1.02 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 60 | -0.52 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 61 | -0.38 Units on a scale | Standard Deviation 1.07 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 62 | -0.53 Units on a scale | Standard Deviation 1.15 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 63 | -0.57 Units on a scale | Standard Deviation 1.1 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 64 | -0.49 Units on a scale | Standard Deviation 1.01 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 65 | -0.39 Units on a scale | Standard Deviation 0.94 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 66 | -0.43 Units on a scale | Standard Deviation 1.18 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 67 | -0.47 Units on a scale | Standard Deviation 0.84 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 68 | -0.35 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 69 | -0.53 Units on a scale | Standard Deviation 0.9 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 70 | -0.43 Units on a scale | Standard Deviation 0.98 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 71 | -0.56 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 72 | -0.72 Units on a scale | Standard Deviation 1.15 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 73 | -0.77 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 74 | -0.54 Units on a scale | Standard Deviation 0.94 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 75 | -0.67 Units on a scale | Standard Deviation 1 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 76 | -0.65 Units on a scale | Standard Deviation 1.22 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 77 | -0.82 Units on a scale | Standard Deviation 1.21 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 78 | -0.57 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 79 | -0.64 Units on a scale | Standard Deviation 1.23 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 80 | -1.04 Units on a scale | Standard Deviation 1.11 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 81 | -0.79 Units on a scale | Standard Deviation 1.05 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 82 | -0.89 Units on a scale | Standard Deviation 1.27 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 83 | 0.13 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 84 | -0.20 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 85 | 0.00 Units on a scale | Standard Deviation 0.87 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 86 | -0.38 Units on a scale | Standard Deviation 0.48 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 87 | -0.83 Units on a scale | Standard Deviation 0.58 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 88 | -0.88 Units on a scale | Standard Deviation 0.48 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 89 | 0.00 Units on a scale | Standard Deviation 0.71 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 90 | 0.25 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 91 | -0.50 Units on a scale | Standard Deviation 0 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 92 | 0.50 Units on a scale | Standard Deviation 0.71 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 93 | 0.50 Units on a scale | Standard Deviation 0.71 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 94 | 0.50 Units on a scale | — |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Week 95 | 0.00 Units on a scale | — |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Time of First Pd | -0.45 Units on a scale | Standard Deviation 0.93 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Cough: Time of Last Tx Dose | -0.29 Units on a scale | Standard Deviation 0.91 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 1 | 0.16 Units on a scale | Standard Deviation 0.81 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 2 | 0.15 Units on a scale | Standard Deviation 0.82 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 3 | 0.12 Units on a scale | Standard Deviation 0.7 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 4 | 0.17 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 6 | 0.16 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 7 | 0.25 Units on a scale | Standard Deviation 0.92 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 8 | 0.24 Units on a scale | Standard Deviation 0.96 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 10 | 0.16 Units on a scale | Standard Deviation 0.92 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 11 | 0.26 Units on a scale | Standard Deviation 0.96 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 12 | 0.22 Units on a scale | Standard Deviation 0.9 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 13 | 0.30 Units on a scale | Standard Deviation 1.02 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 14 | 0.22 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 15 | 0.19 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 16 | 0.26 Units on a scale | Standard Deviation 1.02 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 27 | 0.24 Units on a scale | Standard Deviation 1.06 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 28 | 0.25 Units on a scale | Standard Deviation 0.97 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 29 | 0.20 Units on a scale | Standard Deviation 1.01 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 30 | 0.21 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 33 | 0.17 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 34 | 0.24 Units on a scale | Standard Deviation 1.04 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 35 | 0.23 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 36 | 0.22 Units on a scale | Standard Deviation 1.02 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 37 | 0.24 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 39 | 0.19 Units on a scale | Standard Deviation 1.01 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 40 | 0.19 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 41 | 0.16 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 42 | 0.17 Units on a scale | Standard Deviation 0.92 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 43 | 0.22 Units on a scale | Standard Deviation 0.9 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 44 | 0.23 Units on a scale | Standard Deviation 0.92 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 45 | 0.21 Units on a scale | Standard Deviation 0.9 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 46 | 0.23 Units on a scale | Standard Deviation 0.89 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 47 | 0.14 Units on a scale | Standard Deviation 0.9 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 48 | 0.14 Units on a scale | Standard Deviation 0.85 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 49 | 0.16 Units on a scale | Standard Deviation 0.9 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 50 | 0.24 Units on a scale | Standard Deviation 0.94 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 51 | 0.30 Units on a scale | Standard Deviation 0.97 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 52 | 0.27 Units on a scale | Standard Deviation 1.02 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 53 | 0.22 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 54 | 0.23 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 55 | 0.16 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 56 | 0.18 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 57 | 0.11 Units on a scale | Standard Deviation 0.91 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 58 | 0.16 Units on a scale | Standard Deviation 0.86 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 59 | 0.07 Units on a scale | Standard Deviation 0.85 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 60 | 0.27 Units on a scale | Standard Deviation 0.94 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 61 | 0.23 Units on a scale | Standard Deviation 0.9 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 62 | 0.16 Units on a scale | Standard Deviation 0.92 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 63 | 0.27 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 64 | 0.14 Units on a scale | Standard Deviation 0.93 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 65 | 0.12 Units on a scale | Standard Deviation 0.95 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 66 | 0.16 Units on a scale | Standard Deviation 0.94 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 67 | 0.26 Units on a scale | Standard Deviation 1.01 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 68 | 0.25 Units on a scale | Standard Deviation 1.03 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 69 | 0.16 Units on a scale | Standard Deviation 1.11 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 70 | 0.07 Units on a scale | Standard Deviation 0.89 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 71 | 0.13 Units on a scale | Standard Deviation 0.89 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 72 | 0.06 Units on a scale | Standard Deviation 0.91 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 73 | 0.09 Units on a scale | Standard Deviation 0.99 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 74 | 0.27 Units on a scale | Standard Deviation 1.19 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 75 | 0.45 Units on a scale | Standard Deviation 1.31 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 76 | 0.02 Units on a scale | Standard Deviation 1.1 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 77 | 0.09 Units on a scale | Standard Deviation 1.17 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 78 | 0.03 Units on a scale | Standard Deviation 1.19 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 79 | 0.19 Units on a scale | Standard Deviation 1.18 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 80 | -0.26 Units on a scale | Standard Deviation 0.8 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 81 | -0.17 Units on a scale | Standard Deviation 1.15 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 82 | 0.18 Units on a scale | Standard Deviation 1.54 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 83 | 0.45 Units on a scale | Standard Deviation 1.22 |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score | Dyspnoea: Week 84 | 0.60 Units on a scale | Standard Deviation 1.1 |
Secondary
Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1
DOR is defined as the time interval from the date of the first occurrence of a CR or PR (whichever status is recorded first) until the first date that progressive disease or death is documented, whichever occurs first.
Time frame: Randomization up to approximately 25 months
Population: DOR was assessed in participants who had an objective response as determined by the investigator using RECIST v1.1.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 | 6.4 Months |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 | 9.5 Months |
p-value: 0.002495% CI: [0.45, 0.85]Log Rank
Secondary
Maximum Observed Serum Atezolizumab Concentration (Cmax)
Maximum observed serum atezolizumab concentration (Cmax) after infusion (Arm A)
Time frame: Day 1 of Cycle 1 (Cycle length=21 days)
Population: PK analyses were based on PK observations from all patients who received atezolizumab, carboplatin, cisplatin or pemetrexed treatment and who provided at least one evaluable PK sample.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Maximum Observed Serum Atezolizumab Concentration (Cmax) | 403 μg/mL | Standard Deviation 118 |
Secondary
Minimum Observed Serum Atezolizumab Concentration (Cmin)
Minimum observed serum atezolizumab concentration (Cmin) prior to infusion at selected cycles (Arm A)
Time frame: Predose (Prd; 0 hour [h]) on D1 of Cy 2,3,4,8,16 (Cy length=21 days) and thereafter on D1 of every 8th cycle (up to approximately 25 months)
Population: PK analyses were based on PK observations from all patients who received atezolizumab, carboplatin, cisplatin or pemetrexed treatment and who provided at least one evaluable PK sample.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cy2D1 | 69.8 μg/mL | Standard Deviation 32.3 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cy3D1 | 115 μg/mL | Standard Deviation 51.5 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cy4D1 | 151 μg/mL | Standard Deviation 69.9 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cy8D1 | 221 μg/mL | Standard Deviation 101 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cy16D1 | 234 μg/mL | Standard Deviation 86.7 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cy24D1 | 257 μg/mL | Standard Deviation 95.1 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Treatment Discontinuation Visit | 129 μg/mL | Standard Deviation 93.1 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Day 120 Post Last Dose | 13.4 μg/mL | Standard Deviation 19.4 |
Secondary
Overall Survival Rate at Year 1
The Overall Survival Rate at the 1-year landmark time point is defined as the probabilities that participants are alive 1-year after randomization.
Time frame: Year 1
Population: The ITT population was defined as all randomized patients, whether or not the patients received the assigned treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Overall Survival Rate at Year 1 | 55.04 Percentage |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Overall Survival Rate at Year 1 | 59.72 Percentage |
p-value: 0.260695% CI: [-3.47, 12.83]z test
Secondary
Overall Survival Rate Year 2
The Overall Survival Rate at the 2-year landmark time point is defined as the probabilities that participants are alive 2-years after randomization.
Time frame: Year 2
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Overall Survival Rate Year 2 | 34.01 Percentage |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Overall Survival Rate Year 2 | 39.13 Percentage |
p-value: 0.20995% CI: [-2.87, 13.11]Z-test
Secondary
Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) Assessed by the Investigator Using RECIST V1.1
An objective response is defined as either an unconfirmed CR or a PR, as determined by the investigator using RECIST v1.1. Objective Response Rate is defined as the proportion of patients who had an objective response.
Time frame: Randomization up to approximately 25 months
Population: The ITT population was defined as all randomized patients, whether or not the patients received the assigned treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) Assessed by the Investigator Using RECIST V1.1 | Responders | 37.4 Percentage of Participants |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) Assessed by the Investigator Using RECIST V1.1 | Non-Responders | 62.6 Percentage of Participants |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) Assessed by the Investigator Using RECIST V1.1 | Responders | 51.7 Percentage of Participants |
| Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed | Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) Assessed by the Investigator Using RECIST V1.1 | Non-Responders | 48.3 Percentage of Participants |
p-value: 0.000595% CI: [5.9, 22.7]Cochran-Mantel-Haenszel
Secondary
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) of Atezolizumab
Baseline prevalence and post-baseline incidence of anti-drug antibodies (ADA) to Atezolizumab in the Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)
Time frame: Prd (0 h) on D1 of Cy1,2,3,4,8,16 (Cy length=21 days) and thereafter on D1 of every 8th cycle, at treatment discontinuation & then every 30 days (up to 120 days) after last dose of atezolizumab (up to app 25 months)
Population: The ADA evaluable population was defined as patients with a non-missing baseline ADA sample and \>=1 non-missing post-baseline ADA sample.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) of Atezolizumab | Baseline Evaluable Participants | 1.8 Percentage of Participants |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) of Atezolizumab | Post-Baseline Evaluable Participants | 35.4 Percentage of Participants |
Secondary
Plasma Concentrations for Carboplatin in Arm A(Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)
Time frame: Prd (0 h), 5-10 minutes (mins) before end of carboplatin infusion (infusion duration=1-2 h), 1 h post-infusion on D1 of Cy1,3 (Cy length=21 days)
Population: PK analyses were based on PK observations from all patients who received atezolizumab, carboplatin, cisplatin or pemetrexed treatment and who provided at least one evaluable PK sample.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Plasma Concentrations for Carboplatin in Arm A(Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) | Cy1D1 Predose | NA ng/mL | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Plasma Concentrations for Carboplatin in Arm A(Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) | Cy1D1 Before End of Infusion | 14900 ng/mL | Standard Deviation 4260 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Plasma Concentrations for Carboplatin in Arm A(Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) | Cy1D1 Post Infusion | 12800 ng/mL | Standard Deviation 4470 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Plasma Concentrations for Carboplatin in Arm A(Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) | Cy3D1 Predose | 220 ng/mL | Standard Deviation 83.8 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Plasma Concentrations for Carboplatin in Arm A(Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) | Cy3D1 Before End of Infusion | 17900 ng/mL | Standard Deviation 4390 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Plasma Concentrations for Carboplatin in Arm A(Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) | Cy3D1 Post Infusion | 13900 ng/mL | Standard Deviation 4080 |
Secondary
Plasma Concentrations for Cisplatin in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)
Time frame: Prd (0 h), 5-10 mins before end of cisplatin infusion (infusion duration=30-60 mins), 1 h post-infusion on D1 of Cy1,3 (Cy length=21 days)
Population: PK analyses were based on PK observations from all patients who received atezolizumab, carboplatin, cisplatin or pemetrexed treatment and who provided at least one evaluable PK sample.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Plasma Concentrations for Cisplatin in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) | Cy1D1 Predose | NA ng/mL | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Plasma Concentrations for Cisplatin in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) | Cy1D1 Before End of Infusion | 3630 ng/mL | Standard Deviation 589 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Plasma Concentrations for Cisplatin in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) | Cy1D1 Post Infusion | 2400 ng/mL | Standard Deviation 360 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Plasma Concentrations for Cisplatin in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) | Cy3D1 Predose | 290 ng/mL | Standard Deviation 86.1 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Plasma Concentrations for Cisplatin in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) | Cy3D1 Before End of Infusion | 3020 ng/mL | Standard Deviation 968 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Plasma Concentrations for Cisplatin in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) | Cy3D1 Post Infusion | 2740 ng/mL | Standard Deviation 543 |
Secondary
Plasma Concentrations for Pemetrexed in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)
Time frame: Prd (0 h), 5-10 mins before end of pemetrexed infusion (infusion duration=10 mins), 1 h post-infusion on D1 of Cy1,3 (Cy length=21 days)
Population: PK analyses were based on PK observations from all patients who received atezolizumab, carboplatin, cisplatin or pemetrexed treatment and who provided at least one evaluable PK sample.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Plasma Concentrations for Pemetrexed in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) | Cy1D1 Predose | NA ng/mL | — |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Plasma Concentrations for Pemetrexed in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) | Cy1D1 Before End of Infusion | 86500 ng/mL | Standard Deviation 41600 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Plasma Concentrations for Pemetrexed in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) | Cy1D1 Post Infusion | 43600 ng/mL | Standard Deviation 15800 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Plasma Concentrations for Pemetrexed in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) | Cy3D1 Predose | 1.83 ng/mL | Standard Deviation 0.681 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Plasma Concentrations for Pemetrexed in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) | Cy3D1 Before End of Inufsion | 79400 ng/mL | Standard Deviation 44400 |
| Arm B (Carboplatin or Cisplatin + Pemetrexed) | Plasma Concentrations for Pemetrexed in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) | Cy3D1 Post Infusion | 50100 ng/mL | Standard Deviation 26100 |